Home > Companies > HOSMAC India Pvt. Ltd.

HOSMAC India Pvt. Ltd.

hosmac.com

Hosmac India Private Limited is a pioneering name in the field of Hospital Planning & Management consultancy in India. Since its inception in 1996, Hosmac has grown rapidly to become a Unique hub of skill sets which cuts across various facets of a health care facility be it architecture, engineering, management, or information technology. "In a span of 15 years, Hosmac has notched up an impressive string of projects in India and abroad. Hosmac provides the entire range of services that any health care service provider, may require: undertaking market research, feasibility studies, detailed architectural design, project co-ordination, equipment procurement, commissioning assistance, conducting an operational audit for existing hospitals.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

Business Insights, PHARMACY MARKET

VERO BIOTECH ANNOUNCES FDA APPROVAL FOR ITS SECOND-GEN GENOSYL DS

VERO Biotech | February 03, 2023

On February 2, 2023, VERO Biotech Inc., a commercial-stage biotechnology company focused on neonatal intensive care and the acute care hospital community, announced that FDA has approved its innovative second-generation GENOSYL® Inhaled Nitric Oxide (iNO) delivery system for use in the operating room with rebreathing anesthesia. The second generation GENOSYL® DS is now the first and only iNO delivery device approved for use in both rebreathing and non-rebreathing anesthesia procedu...

PHARMACY MARKET

HALOZYME ANNOUNCES POSITIVE CLINICAL DATA OF ITS HIGH-VOLUME AUTO-INJECTOR DEMONSTRATING SUCCESSFUL RAPID SUBCUTANEOUS DRUG DELIVERY

PR Newswire | October 19, 2023

Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injecti...

Pharma Tech

TONIX PHARMACEUTICALS COMPLETES ENROLLMENT IN POTENTIALLY NDA-ENABLING PHASE 3 RESILIENT TRIAL OF TNX-102 SL FOR MANAGEMENT OF FIBROMYALGIA

Globenewswire | August 02, 2023

Tonix Pharmaceuticals Holding Corp. a biopharmaceutical company, announced that it has completed enrollment of its potentially final, confirmatory Phase 3 RESILIENT trial of TNX-102 SL (cyclobenzaprine HCL sublingual tablets) 5.6 mg in fibromyalgia and expects topline data next quarter. A total of 457 participants were randomized. TNX-102 SL is in development as a non-opioid, centrally acting analgesic, to be taken daily at bedtime for the management of fibromyalgia. If successful, w...

Business Insights

ENABLE INJECTIONS ENHANCES BOARD WITH ADDITION OF JOHN DEFORD, PH.D.

Enable Injections, Inc. | August 12, 2022

Enable Injections, Inc. a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D. to the company's Board of Directors, effective July 29, 2022. Enable Injections' enFuse is an innovative drug delivery technology designed to subcutaneously (SC) deliver large volumes of up to 50mL for a wide range of therapies and diseases, dedicated to improving the patient ...

Business Insights, PHARMACY MARKET